Rasagiline: a second-generation MAO-B inhibitor for the treatment of Parkinson’s disease

Authors

  • M.V. Polivoda Medical Center «Panacea», Kherson, Ukraine

DOI:

https://doi.org/10.22141/2224-0713.16.7.2020.218700

Keywords:

rasagiline, Parkinson’s disease, monotherapy, combination therapy, Unified Parkinson’s Disease Rating Scale

Abstract

Parkinson’s disease is the second most common neurodegenerative disorder, affecting 1 to 2 % of people older than 60 years. Rasagiline is a potent and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for the treatment of Parkinson’s disease. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early Parkinson’s disease and as adjunctive therapy in advanced Parkinson’s disease. Rasagiline has been shown to have disease-modifying, neuroprotective and anti-apoptotic effects. The data on its effectiveness in motor disorders in Parkinson’s disease and the rate of development of the effect against the background of its administration are presented. At the same time, taking rasagiline is not accompanied by serious adverse events, both with monotherapy and in combination with levodopa and dopamine agonists.

References

Marino B.L.B., de Souza L.R., Sousa K.P.A. et al. Parkinson’s Disease: A Review from Pathophysiology to Treatment. Mini Rev. Med. Chem. 2020. 20(9). 754-767.

Szökő É., Tábi T., Riederer P., Vécsei L., Magyar K. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease. J. Neural. Transm. (Vienna). 2018 Nov. 125(11). 1735-1749.

Stocchi F., Fossati C., Torti M. Rasagiline for the treatment of Parkinson’s disease: an update. Expert Opin. Pharmacother. 2015. 16(14). 2231-41.

Leegwater-Kim J., Bortan E. The role of rasagiline in the treatment of Parkinson’s disease. Clin. Interv. Aging. 2010 May 25. 5. 149-56.

Peretz C., Segev H., Rozani V. et al. Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study. Clin. Neuropharmacol. 2016. 39(5). 227-231. doi: 10.1097/WNF.0000000000000167.

Müller T., Hoffmann J.A., Dimpfel W., Oehlwein C. Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease. J. Neural. Transm. (Vienna). 2013 May. 120(5). 761-5.

Blandini F. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson’s disease? CNS Drug Rev. 2005. 11(2). 183-194. doi: 10.1111/j.1527-3458.2005.tb00269.x

Bar-Am O., Weinreb O., Amit T., Youdim M.B. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J. Neurochem. 2010 Mar. 112(5). 1131-7. doi: 10.1111/j.1471-4159.2009.06542.x. Epub 2009 Dec 10. PMID: 20002521.

McDermott M.P., Jankovic J., Carter J. et al. Factors predictive of the need for levodopa therapy in early, untreated Parkinson’s di-sease. The Parkinson Study Group. Arch. Neurol. 1995. 52. 565-570. doi: 10.1001/archneur.1995.00540300037010.

Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch. Neurol. 2002. 59. 1937-1943. doi: 10.1001/archneur.59.12.1937.

Pistacchi M., Martinello F., Gioulis M., Zambito Marsala S. Rasagiline and rapid symptomatic motor effect in Parkinson’s disease: review of literature. Neurol Ther. 2013. 3(1). 41-66. Published 2013 Dec 17. doi: 10.1007/s40120-013-0014-1.

Olanow C.W., Hauser R.A., Jankovic J. et al. A randomi-zed, double-blind, placebocontrolled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson’s disease (The ADAGIO Study): rationale, design, and baseline characteristics. Movement Disord. 2008. 23. 2194-2201.

Левин О.С. Ранняя терапия болезни Паркинсона разагилином (Азилектом) замедляет прогрессирование заболевания: результаты исследования. Фарматека. 2010. 5(199).75-80.

Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol. 2005. 62. 241-248. doi: 10.1001/archneur.62.2.241.

Rascol O., Brooks D.J., Melamed E. et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005. 365. 947-954. doi: 10.1016/S0140-6736(05)71083-7.

Maruyama W., Youdim M.B., Naoi M. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann. NY Acad. Sci. 2001 Jun. 939. 320-9. doi: 10.1111/j.1749-6632.2001.tb03641.x. PMID: 11462787.

Zambito Marsala S., Vitaliani R., Volpe D. et al. Rapid onset of efficacy of rasagiline in early Parkinson’s disease. Neurol. Sci. 2013. 34. 2007-2013. doi: 10.1007/s10072-013-1437-2.

Deumens R., Blokland A., Prickaerts J. Modeling Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 2002. 175. 303-17.

Chang Y., Wang L.B., Li D., Lei K., Liu S.Y. Efficacy of rasagiline for the treatment of Parkinson’s disease: an updated meta-analysis. Ann. Med. 2017 Aug. 49(5). 421-434.

Clarke C.E., Patel S., Ives N. et al. Should treatment for Parkinson’s disease start immediately on diagnosis or delayed until functional disability develops? Mov. Disord. 2011. 26. 1187-93.

Marconi S., Zwingers T. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson’s disease. Eur. Rev. Med. Pharmacol. Sci. 2014. 18. 1879-82.

Minguez-Minguez S., Solis-Garcia Del Pozo J., Jordan J. Rasagiline in Parkinson’s disease: a review based on meta-analysis of clinical data. Pharmacol. Res. 2013. 74. 78-86.

Ives N.J., Stowe R.L., Marro J. et al. Monoamine oxidase type B inhibitors in early Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ. 2004. 329. 593.

Rascol O., Goetz C., Koller W. et al. Treatment interventions for Parkinson’s disease: an evidence based assessment. Lancet. 2002. 359. 1589-98.

Jiang D.Q., Wang H.K., Wang Y. et al. Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review. Neurol. Sci. 2020 Jan. 41(1). 101-109.

Korczyn A.D. Drug treatment of Parkinson’s disease. Dialogues Clin. Neurosci. 2004. 6. 315-22.

Hauser R.A., Silver D., Choudhry A., Eyal E., Isaacson S.; ANDANTE study investigators. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s disease. Mov. Disord. 2014 Jul. 29(8). 1028-34. doi: 10.1002/mds.25877. Epub 2014 Jun 11. PMID: 24919813.

Published

2020-09-01

Issue

Section

To practicing Neurologist